Location:Home > Faculty > Faculty and Staff
Faculty and Staff
Faculty and Staff
Ding Kan

Professor/Ph.D candidate supervisor, Principal Investigator
Academic title:
Personal Website:
Postal Code:
Mailing Address:
555 Zu Chong Zhi Road, Zhang Jiang Hi-Tech Park, Pudong, Shanghai, P.R.China

Dr.DING Kan is an active professor and a principal investigator in Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He was granted The Grant of '100 Talents Program' of Chinese Academy of Sciences in 2007, and the National Natural Science Foundation Distinguished Young Scholars of China in 2011.

Dr.DING Kan got his M.Sc. degree in pharmacognosy in 1996. Then he registered as a Ph. D. student and work with Prof. FANG Jinian as his mentor in Shanghai Institute of Materia Medica, Chinese academy of sciences from 1996 to 1999. He focused on the study of structure and bioactivity of polysaccharide. He got his Ph. D. degree in 1999 and then was recruited as a postdoctoral fellow by Lund University in Sweden, a research fellow associate by University of California, Irvine and a research fellow by Massachusetts General Hospital, Harvard Medical School in U. S. A., embarking on the glycobiology study on the structure and function of cell membrane proteoglycan in tumor.

He was recruited as one of scientists in “Hundred Talents Program” of the Chinese Academy of Sciences and has been working as full professor since 2005 in Shanghai Institute of Materia Medica, Chinese academy of sciences. He succeeded in the grant application of National Science Fund for Distinguished Young Scholars of China in 2011. He focuses on the study of bioactivities of polysaccharides and oligosaccharides from traditional Chinese medicine, the relationship between structure and bioactivities, the structure and function of proteoglycan in tumor. In addition, he also tries to discover new target for glycan-based drug development. So far, he has obtained 22 grants, including State Key Program of National Natural Science of China, the National Natural Science Foundation of Science Fund for Distinguished Young Scholars, National Natural Science Foundation, Major National Science and Technology projects: Major New Drug Candidate Drugs, National Science and Technology Major Projects for Key Techniques, Strategic Priority Research Program of the Chinese Academy of Sciences, National High-Tech R&D Program of China (863 Program), “Hundred Talents Project”of the Chinese Academy of Sciences, etc., and took part in 7 projects including National Program on Key Basic Research Project (973 Program). There are around 21-23 members in his lab. He has published 72 papers on the international journal including J Cell Biol, Oncogene, J Biol Chem, Oncotarget, Glycobiology, Cancer Lett, Sci Rep, Carbohydr Res and Carbohydr Polyms, In addition, one book entitled “The structure, function the their bioactive mechanism of polysaccharides from traditional Chinese medicine” has been issued under his general editorship. He also published three chapters in Advanced medicinal Chemistry and the Extraction and separation of Active Components in Traditional Chinese Medicine, and filed 47 national and international patents (33 patents authorization have been obtained, one of them was granted by U.S.A., European and Japanese Patent Bureau). 

01/01/2006 - present,Professor,Principal Investigator,Glycochemistry & Glycobiology Lab in Shanghai Institute of Materia Medica, Chinese Academy of Sciences,China
01/01/2004 - 11/01/2005,Research fellow,Neurosciences Center in Massachusetts General Hospital/Harvard Medical School (Boston, U.S.A.)
12/01/2001 - 12/01/2003,Research Fellow associate in Department of Cell and Developmental Biology in University of California, Irvine (Irvine, U.S.A.)
09/01/1999 - 11/01/2001,Postdoctoral Fellow,in Department of Cell and Molecular Biology in Lund University (Lund, Sweden)
08/01/1986 - 08/31/1993,Instructor,Jiangsu Pharmaceutical School,Jiangsu,China

09/01/1993 - 07/01/1996,Ph.D. in Organic Chemistry in Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Shanghai, China)
09/01/1996 - 07/01/1999,M.Sc. in Pharmacognosy in China Pharmaceutical University (Nanjing,China)

Research Directions

We focus on study of structure and function of glycan and glycan-based drug development.
This includes:
1.Structure, bioactivity, and their mechanism of polysaccharide from traditional Chinese medicine;
2.The function of synthesis and degradation enzymes of heparin sulfate chain in neuritogenesis;
Function of microRNAs in angiogenesis probed by glycan;
4.Targets discovery of glycans and the mechanism underlying actions of anti-cancer glycans.

Social Titles

1.Participating investigator of the Consortium for Functional Glycomics, U.S.A.
2.Vice chairman of Chinese Society of Glycobiology
3.Consulting expert for China Food and Drug Administration
Associate editor for Carbohydrate Research
Editorial board member of Chinese Journal of Natural Medicine
Member of consulting committee in Dalian University of Technology


Awards & Honors

1. 01/2017, The first prize of Science and Technology in Guangdong Province
2. 01/2016, Outstanding Academic Leader in Shanghai
3. 12/2011, The National Natural Science Foundation for Distinguished Young Scholars of China
4. 01/2007, “Hundred Talent Program” of Chinese Academy of Sciences
5. 09/2006, “Pujiang Talent Program” in Shanghai
6. 2/2000, The second place of Natural Science Award in Chinese Academy of Sciences
7. 12/2000, The second place of Progress of Science and Technology Award in Shanghai

1.Structure and catalytic mechanism of Glce in neuritogenesis
2.Function of Glce and heparanase in neuritogenesis
3.Function of MicroRNAs in angiogenesis probed by glycans
4.Targets discovery of polysaccharide and the underlying mechanism
5.The mechanism underlying polysaccharide uptake in intestinal cells

Grants & Research Projects

1. Strategic Priority Research Program of the Chinese Academy of Sciences
2. The State Key Program of National Natural Science Foundation of China
3. National Science Fund for Distinguished Young Scholars, National key projects on New Drug program
4. National High-tech R&D program of China (863 program)
5. Chinese National Natural Science Foundation
6. Fund of 100 Talents Program
7. Sub-project of National program on Key Basic Research Project (973 program)


Selected Pubilcations
1.Zhang L, Wang P, Qin Y, Cong Q, Shao C, Du Z, Ni X, Li P*, Ding K*. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene, 2016, Sep 12. doi: 10.1038/onc.2016.306

2.Wang W, Chen H , Zhang L, Qin Y, Cong Q, Wang P, Kan Ding*. A fucoidan from Nemacystus decipiens disrupts angiogenesis through targeting BMP4. Carbohydr. Polym, 2016, 144:305-14.

3.Shen X, Li J, Liao W, Wang J , Chen H, Yao Y, Liu H*, Ding K*. microRNA-149 targets caspase-2 in glioma progression. Oncotarget, 2016, 7(18):26388-99.

4.Chen H, Cong Q, Du Z, Liao W, Zhang L, Yao Y, Ding K*. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Cancer Lett. 2016 382(1):44-52

5.Qin Y, Ke J*, Gu X, Fang J, Wang W, Cong Q, Li J, Tan J, Brunzelle JS, Zhang C, Jiang Y, Melcher K, Li JP, Xu HE*, Ding K*. Structural and functional study of D-glucuronyl C5-epimerase. J Biol Chem. 2015, 290(8):4620-30

6.Xiao F, Qiu H, Cui H, Ni X, Li J, Liao W, Lu N, Ding K*. MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling. Oncogene, 2015, 34(15):1968-78.

7.Wang P, Zhang L, Li P*, Ding K*. An arabinogalactan from flowers of Panax notoginseng inhibits angiogenesis by BMP2/ Smad/Id1 signaling. Carbohydr Polym 2015, 121:328-35.

8.Li J, Fang J, Qin Y, Liao W, Liu H, Zhou Y*, Ding K* Glce regulates PC12 cell neuritogenesis induced by nerve growth factor through activating Smad/Id3 signaling. Biochem J. 2014, 459(2): 405-416

9.Liu H, Zhou L, Shi S, Wang Y, Ni X, Xiao F, Wang S, Li P*, Ding K*. Oligosaccharide G19 inhibits U-87 MG human glioma cells growth in vitro and in vivo by targeting epidermal growth factor (EGF) and activating p53/p21 signaling. Glycobiology, 2014 24(8):748-65.

10.Wang P, Liao W, Fang J, Liu Q, Yao J, Hu M, Ding K*. A glucan isolated from flowers of Lonicera japonica Thunb inhibits aggregation and neurotoxicity of Aβ42. Carbohydr Polym. 2014, 110C:142-147.

11.Cong Q, Shang M, Dong Q, Liao W, Xiao F, Ding K*. Structure and activities of a novel heteroxylan from Cassia obtusifolia seeds and its sulfated derivative. Carbohydr Res. 2014; 393C:43-50

12.Xiao F, Qiu H, Zhou L, Shen X, Yang L, Ding K*. WSS25 inhibits Dicer, downregulating microRNA-210 which targets Ephrin-A3, to suppress human microvascular endothelial cell (HMEC-1) tube formation. Glycobiology. 2013, 23(5):524-35.

13.Cui H, Shao C, Liu Q, Yu W, Fang J, Yu W, Ali A, Ding K*. Heparanase enhances nerve growth factor induced PC12 cell neuritogenesis via the p38 MAPK pathway. Biochem J. 2011, 440(2)273-282.

14.Shen X, Fang J, Lv X, Pei Z, Wang Y, Jiang S, Ding K*. Heparin impairs angiogenesis through inhibition of MicroRNA-10b. J Biol Chem. 2011, 286(30):26616-272.

15.Qiu H, Yang B, Pei ZC, Zhang Z, Ding K*. WSS25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking BMP/SMAD/ID1 signaling. J Biol Chem. 2010, 285(42):32638-46